Skip to content

Study · Non-randomized trial · n = 736 · 2020

3 results

Fixed-Ratio Combination of Insulin and GLP-1 RA in Patients with Longstanding Type 2 Diabetes: A Subanalysis of LixiLan-L.

Blonde L, Berard L, Saremi A, Huang Y, Aroda VR, Raccah D

Diabetes therapy : research, treatment and education of diabetes and related disorders12 Mar 2020Cited by 6 (Europe PMC)

PMID32166620 (opens in a new tab)PMCIDPMC7136373 (opens in a new tab)DOI10.1007/s13300-020-00797-y (opens in a new tab)PepBankPUB-32166620
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with type 2 diabetes, iGlarLixi reduced glycated haemoglobin more than glargine across all diabetes-duration quartiles.

    In plain wordsIn patients with type 2 diabetes, adding lixisenatide to glargine reduced glycated haemoglobin more than glargine across duration groups.

    Peptide
    Lixisenatide
    Outcome
    DecreaseGlycated haemoglobin reduction across duration quartiles
    Study

    n = 736

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    LS mean HbA1c difference
    −0.62
    iGlarLixi vs iGlar, Q4 (longest duration)
    Standard error
    0.13
    LS mean difference, Q4
    P value
    < 0.0001
    Q4

    Source sentences

    Summary
    Across all quartiles, the reduction in glycated haemoglobin was greater with iGlarLixi versus iGlar, and the difference was most pronounced in patients with the longest duration (Q4; least squares mean difference [standard error] - 0.62 [0.13], P < 0.0001).
    1 context sentence
    Summary · context
    We assessed the efficacy and safety of insulin glargine (iGlar) versus iGlarLixi, a fixed-ratio combination of iGlar and lixisenatide, stratified by quartiles (Q) of T2D duration (≤ 7.305 [Q1], > 7.305 to ≤ 10.75 [Q2], > 10.75 to ≤ 15.67 [Q3], and > 15.67 years [Q4]) in the LixiLan-L trial (N = 736).
  2. 02HumanNon-randomized trialEfficacy outcome

    In the longest diabetes-duration quartile, the glycated haemoglobin difference favored iGlarLixi over glargine (-0.62, standard error 0.13, P < 0.0001).

    In plain wordsIn patients with the longest diabetes duration, adding lixisenatide to glargine reduced glycated haemoglobin more than glargine.

    Peptide
    Lixisenatide
    Outcome
    DecreaseGlycated haemoglobin reduction in longest-duration quartile
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    LS mean difference in HbA1c reduction
    −0.62
    iGlarLixi vs iGlar, Q4 (>15.67 years duration)
    SE of LS mean difference
    0.13
    iGlarLixi vs iGlar, Q4 (>15.67 years duration)

    Source sentences

    Summary
    Across all quartiles, the reduction in glycated haemoglobin was greater with iGlarLixi versus iGlar, and the difference was most pronounced in patients with the longest duration (Q4; least squares mean difference [standard error] - 0.62 [0.13], P < 0.0001).
    1 context sentence
    Summary · context
    We assessed the efficacy and safety of insulin glargine (iGlar) versus iGlarLixi, a fixed-ratio combination of iGlar and lixisenatide, stratified by quartiles (Q) of T2D duration (≤ 7.305 [Q1], > 7.305 to ≤ 10.75 [Q2], > 10.75 to ≤ 15.67 [Q3], and > 15.67 years [Q4]) in the LixiLan-L trial (N = 736).
  3. 03HumanNon-randomized trialSafety outcome

    In the longest diabetes-duration quartile, hypoglycaemia rates were 3.3 versus 6.9 events/patient-year with iGlarLixi versus glargine (P < 0.0001).

    In plain wordsIn patients with the longest diabetes duration, adding lixisenatide to glargine reduced low blood sugar events versus glargine.

    Peptide
    Lixisenatide
    Outcome
    DecreaseHypoglycaemia rate in longest-duration quartile
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Hypoglycaemia rate
    3.3 events/patient-year
    iGlarLixi, Q4
    Hypoglycaemia rate
    6.9 events/patient-year
    iGlar, Q4

    Source sentences

    Summary
    Additionally, hypoglycaemia rates were significantly lower with iGlarLixi versus iGlar in patients in Q4 (3.3 vs. 6.9 events/patient-year, P < 0.0001).
    1 context sentence
    Summary · context
    We assessed the efficacy and safety of insulin glargine (iGlar) versus iGlarLixi, a fixed-ratio combination of iGlar and lixisenatide, stratified by quartiles (Q) of T2D duration (≤ 7.305 [Q1], > 7.305 to ≤ 10.75 [Q2], > 10.75 to ≤ 15.67 [Q3], and > 15.67 years [Q4]) in the LixiLan-L trial (N = 736).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.